Centerstone, a nonprofit health system specializing in mental health and substance use disorder treatments, will be holding a ...

Data from the CENTERSTONE study shows single-dose Xofluza reduces transmission of influenza from an infected person to ...

Roche Holdings AG (OTC:RHHBY) released positive topline results of the phase 3 CENTERSTONE study of Xofluza (baloxavir ...

Treatment with baloxavir marboxil significantly reduced the risk of onward transmission of influenza within households.

Roche announces phase III CENTERSTONE study of Xofluza significantly reduces the transmission of influenza viruses: Basel Friday, September 20, 2024, 09:00 Hrs [IST] Roche announc ...

Roche today released positive top-line results of the Phase III CENTERSTONE study of Xofluza (baloxavir marboxil), an ...

Results from a late-stage study on RHHBY's Xofluza show that the drug reduces the transmission of influenza from an infected ...

Data from the CENTERSTONE study shows single-dose Xofluza reduces transmission of influenza from an infected person to household membersThis is the first time that any antiviral used in the treatment ...

Xofluza (baloxavir marboxil), an antiviral medication, achieved its primary endpoint in the phase III CENTERSTONE ...

Centerstone Investors Fund earns an Average Process Pillar rating. The primary contributor to the rating is the firm's retention rate of the firm's portfolio managers, which is 100% over the ...

Roche (RHHBF) unit Genentech said Xofluza antiviral reached the main goal in a global Phase 3 trial, reducting the ...